WAVEMAN · COMPANY

SNY · Sanofi

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

SNY

Name: Sanofi (SNY) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Sanofi

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001121404

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

307

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

307 funds added or opened last quarter

more than 94% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

307 funds added or opened positions in the latest 13F quarter, of 721 holders.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 307 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Sanofi in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Dodge & Cox

28,088,274.0 sh

$1.2B

MORGAN STANLEY

10,702,527.0 sh

$456.6M

Fisher Asset Management, LLC

10,627,088.0 sh

$453.4M

BANK OF AMERICA CORP /DE/

8,008,572.0 sh

$341.6M

Invesco Ltd.

6,798,961.0 sh

$290.0M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Integrity Dividend Summit Fund

$838.4K POSITION · AS OF 2026-04-30

5.6%

VanEck Pharmaceutical ETF

$60.8M POSITION · AS OF 2026-03-31

4.7%

Brown Advisory Sustainable Value ETF

$13.7M POSITION · AS OF 2026-03-31

4.2%

Brown Advisory Sustainable Value Fund

$7.2M POSITION · AS OF 2026-03-31

4.2%

Catalyst/MAP Global Equity Fund

$3.4M POSITION · AS OF 2026-03-31

3.8%

Federated Hermes Enhanced Income ETF

$1.2M POSITION · AS OF 2026-04-30

3.3%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 394 registered trials, 156 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

9 ACTIVE

Phase 2

35 ACTIVE

Phase 3

51 ACTIVE

Phase 4

11 ACTIVE

Not applicable

37 ACTIVE

Multi-phase

13 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
GROSS PROFIT	$33.7B	$31.1B	$29.0B	$28.7B
NET INCOME	$7.9B	$5.6B	$5.4B	$8.5B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE